Janssen to Use Adaptive's NGS Immune Profiling Assay to Study Drug Response | GenomeWeb

NEW YORK (GenomeWeb News) – Adaptive Biotechnologies said today that it has inked a biomarker discovery agreement with Janssen Research & Development.

Under the terms of the agreement, which was facilitated by the Johnson & Johnson Innovation Center, Adaptive will use its targeted next-gen sequencing-based ImmunoSeq assay to study immune response to diseases in order to identify patients more likely to respond to immunology and oncology drugs being developed by Janssen.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.